# A Study of LY2157299 in Participants With Hepatocellular Carcinoma

> **NCT01246986** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 204 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** LY2157299
- **DRUG:** Sorafenib
- **DRUG:** Ramucirumab

## Key facts

- **NCT ID:** NCT01246986
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-30
- **Primary completion:** 2019-06-06
- **Final completion:** 2019-12-24
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2021-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01246986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01246986, "A Study of LY2157299 in Participants With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01246986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*